Christos Argyropoulos MD PhDEnsitrelvir was just approved in Japan for prophylaxis against SARSCOV2 #COVID19
Among 2,041 people living with COVID-19 patients, 30 of 1,030 who received it developed the disease within 10 days compared with 91 of 1,011 (9.0%) in the placebo group for relative risk ⬇️67%.
Among 2,041 people living with COVID-19 patients, 30 of 1,030 who received it developed the disease within 10 days compared with 91 of 1,011 (9.0%) in the placebo group for relative risk ⬇️67%.